Medical Oncologist @DanaFarber ; Co-director, Prostate Cancer Program @Harvard Cancer Consortium; EIC @ASCO Daily News, FCOI https://nitter.gq/t.co/ywWAdZmBWt
Salt Lake City, UT
Joined January 2016
- Tweets15.1K
- Following784
- Followers17.5K
- Likes25.4K
Pinned Tweet
Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
Neeraj Agarwal, MD, FASCO retweeted
🗳️ Voting is open for the 2027 @ASCO Election!
Here’s a quick step-by-step:
1⃣Go to asco.org/election and open the voting link
2⃣Log in with your @ASCO membership credentials
3⃣Review the candidates and cast your votes
My endorsement: For Board of Directors – Undesignated Member (4-year term), I’m voting for @montypal
Just in @EUplatinum 👉#APCCC2026 report on high-risk localised, locally advanced & recurrent #ProstateCancer: 133 experts from across the world👉Highlights risk-adapted care & evidence gaps for trials. @APCCC_ @PCF_Science @UroToday @OncoAlert 👉link: shorturl.at/YAcnY
Neeraj Agarwal, MD, FASCO retweeted
Amazing APCCC prostate consensus statement out today on early prostate cancer. Experts from around the world come together in Lugano to address the most contravercial issues. @Silke_Gillessen @neerajaiims @DrChoueiri @OncoAlert kwnsfk27.r.eu-west-1.awstrac…
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
Neeraj Agarwal, MD, FASCO retweeted
It was a fantastic #ESMO26 full of practice changing clinical trial and data that will make an impact for cancer patients. I can’t wait for #ESMO27 in Barcelona.
@myESMO @DanaFarber @DanaFarber_GU @OncoAlert
Neeraj Agarwal, MD, FASCO retweeted
DASL-HiCap trial #ESMO26 @myESMO @Silke_Gillessen @ANZUPtrials @APCCC_Lugano @oncodaily @OncoAlert
🔴ADT+Darolutamide+prostate/pelvis RT ⬆️ MFS-CI
🟠≠ definition "very high risk" & PSMA/PET not included
🟢Improved MFS-CI, PSA-PFS, CRPC, subsquent tx. But final analysis & OS awaited!
🔵3 studies: STAMPEDE, ENZARAD & DASL-HiCap. ≠ populations, ≠RT to pelvis, N1 benefit across trials.
🟣Good outcomes, need biomarkers
Neeraj Agarwal, MD, FASCO retweeted
Bienvenidos a Madrid para #ESMO26
🎥 Nueva Educational Capsule | @GuardConsortium
🇪🇸 TALAPRO-3: ¿Un nuevo paso para los PARP inhibitors en prostate cancer hormonosensible?
Dr. Joaquín Mateo (@quimmateo) from @VHIO in Barcelona breaks down the TALAPRO-3 trial, presented at ASCO 2026 and published in the New England Journal of Medicine, alongside @AzadOncology, @neerajaiims and colleagues.
🧬 What did TALAPRO-3 show?
This phase 3 trial evaluated talazoparib + enzalutamide versus placebo + enzalutamide in patients with HRR-altered metastatic hormone-sensitive prostate cancer (mHSPC).
🔹 599 patients enrolled across both treatment arms.
🔹 Radiographic progression-free survival (rPFS) at 3 years: 77% vs. 56% (HR 0.48; 95% CI 0.36–0.65; p<0.001).
🔹 Overall survival (OS): 78% vs. 72% at 3 years in the interim analysis (HR 0.77; 95% CI 0.56–1.04). OS data remain immature.
🔹 Safety matters: Grade ≥3 anemia occurred in 51% of patients receiving talazoparib.
💡 La gran pregunta: ¿Estamos ante un cambio en el papel de los PARP inhibitors, moving them earlier into the hormone-sensitive setting?
Watch Dr. Mateo’s analysis and join the conversation. 👇
🔗 nejm.org/doi/full/10.1056/NE…
#GuardConsortium #TALAPRO3 #ProstateCancer #ASCO2026
GU Oncology colleagues: @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @OncBrothers @Helena_de_Palma @DrIacovelli @mjuanfi81
OncoALert faculty: @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @AndreaNecchi @scocmem
Neeraj Agarwal, MD, FASCO retweeted
Excited to share our newly published article in Nature Reviews Urology @NatRevUrol, “Rare Prostate Cancer Histologies: Detection, Characteristics and Treatment,” led by Drs. Spiess and Melão. @SpiessPhilippe @UrogerliMD @katcollmd @neerajaiims @PGrivasMDPhD @AndreaNecchi
This comprehensive review highlights the diagnostic, molecular, and clinical features of both common and rare prostate cancer histologic subtypes, including mucinous, intraductal, ductal, neuroendocrine, sarcomatoid, and adenoid cystic (basal cell) carcinomas. We also explore advances in pathology, imaging, molecular profiling, immunotherapy and precision oncology, while addressing important unmet clinical needs and future research directions.
Full article available:
nature.com/articles/s41585-0…
Neeraj Agarwal, MD, FASCO retweeted
Dear #ESMO26 We Are ALL @OncoAlert 🚨
For Colleagues...By Colleagues
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @scocmem @niklas_kluemper @Markuseckstein3 @AndreaNecchi @weoncologists
Neeraj Agarwal, MD, FASCO retweeted
A long-awaited breakthrough in cancer vaccines.
One patient. One tumor. One personalized mRNA vaccine.
INTErpath-001 brings this vision closer to clinical reality. Are we ready to deliver it?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @ProfGLongMIA @FAndreMD @curijoey @YJanjigianMD
Neeraj Agarwal, MD, FASCO retweeted
🚨 #ESMO26 #Podium2Screen: LITESPARK-012 in advanced #RCC
Our @OncoAlert founding faculty @DrChoueiri presents
➡️ Adding belzutifan or CTLA-4 blockade (quavonlimab) to pembrolizumab + lenvatinib did NOT improve PFS, OS or ORR (n=1688)
@tompowles1 @MVossMD @ERPlimackMD
@HowardGurney @brian_rini
➡️ Higher discontinuation rates in the triplet arms
Pembro + lenvatinib remains a 1L standard 👇
#KidneyCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Neeraj Agarwal, MD, FASCO retweeted
Sunday morning GU session: 2 phase III published in @Annals_Oncology —congrats Annals team, @myESMO and EIC @tompowles1 ! #ESMO26
@DanaFarber_GU @DanaFarber @OncoAlert
Neeraj Agarwal, MD, FASCO retweeted
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Neeraj Agarwal, MD, FASCO retweeted
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Neeraj Agarwal, MD, FASCO retweeted
🇮🇳 Promising practice-changing data from @TataMemorial India 🇮🇳 at #ESMO2026!
Phase III trial (n=475) in technically unresectable oral cancer:
Weekly paclitaxel-carboplatin + oral metronomic therapy (PCm) vs DCF
✅ Higher response rates
✅ Greater conversion to resectability
✅ Significantly less toxicity
✅ Non-inferior overall survival
✅ Outpatient-friendly, without central line
2-year OS: 38.9% vs 29.4%, favouring PCm.
An innovative, pragmatic, potentially more accessible and cost effective regimen from India!
👏 Congratulations @VanitaNoronha and the entire team from @TataMemorial
#ESMO26 @OncoAlert @oncodaily @myESMO @montypal @neerajaiims
Neeraj Agarwal, MD, FASCO retweeted
Exciting work from our own @DanaFarber_GU stars @PrafulRavi1 and @aloktewar!
Promising ctDNA analysis in #mCRPC treated with ¹⁷⁷Lu-PSMA-617:
• Baseline tumor fraction is prognostic
• Genomic alterations linked to resistance
• Acquired resistance is heterogeneous
Closer toward biomarker-guided radioligand therapy!
@DanaFarber_GU @DanaFarber @myESMO @OncoAlert #ESMO26
Neeraj Agarwal, MD, FASCO retweeted
@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC.
@oncoalert #ESMO26 @myESMO
Neeraj Agarwal, MD, FASCO retweeted
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
Neeraj Agarwal, MD, FASCO retweeted
A targeted dual-protein lock. A completely new way of thinking about cancer therapy. #JNJ6143 is a first-in-class #RIPTAC™ oral small molecule designed to selectively bring together two proteins—AR and BRD4—inside prostate cancer cells, creating a ternary complex that disrupts cancer-driving biology and triggers tumor cell death. @BGarmezy showcased this at #ESMO2026 today and it has been the talk of the meeting! #ProstateCancer #Oncology #CancerResearch #PrecisionMedicine
